Neoadjuvant Chemotherapy with FLEP Therapy for Advanced Gastric Cancer: Evaluation of Intraaortic and Intravenous FLEP Infusions
To improve the survival rate of patients with gastric cancer, several therapeutic modalities have been introduced to the field of clinical trials. Among those modalities, the concept of neoadjuvant chemotherapy has been developed to manage the far-advanced gastric cancer. FLEP-5-fluorouracil (5-FU), leucovorin, etoposide, and cis-diamminedichloroplatinum (CDDP) —therapy, which was introduced by Nakajima , is one of the neoadjuvant regimens. The development of this regimen was based on the results of previous evaluations showing the excellent role of biochemical modulation of 5-FU with leucovorin and the synergisms between CDDP and etoposide [2, 3, 4] and between 5-FU and CDDP [5,6]. The effect of chemotherapy depends on the drug concentration at the tissue level. Usually the drug concentration in tumor tissue is higher with intraarterial infusion than with intravenous infusion. Systemic drug toxicities are expected to be less with intraarterial administration than with intravenous injection . According to the above-mentioned rationale, changing the administration route from intravenous to intraarterial may become another way to enhance the efficacy of chemotherapeutic agents. Investigators have tried to evaluate the clinical results of FLEP therapy according to the route of administration, such as intraaortic (IAo) or intravenous (IV), in patients with unresectable gastric cancer.
KeywordsGastric Cancer Hepatic Metastasis Gastric Outlet Obstruction Intraarterial Infusion Distant Lymph Node Metastasis
Unable to display preview. Download preview PDF.
- 1.Nakajima T (1991) Adjuvant and neoadjuvant chemotherapy in gastric cancer. Cancer Chemother 6:245Google Scholar
- 5.Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke J, Misset J, Schwarzenberg L, Fourtillan JB, Gaget H, Mathe G (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685–696PubMedGoogle Scholar
- 6.Louvet C, de Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, Delfau S, Varette C, Gonzalez CG, Krulik M (1991) High dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 2:229–230PubMedCrossRefGoogle Scholar
- 7.Stephenes FO, Adams BG, Crea P (1986) Intraarterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 162:370–374Google Scholar
- 8.WHO (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. World Health Organization, GenevaGoogle Scholar
- 9.Japan Society for Cancer Therapy (1986) Japanese criteria for the evaluation of the direct effects of cancer chemotherapy for solid tumors. J Jpn Soc Cancer Ther 21:931–942Google Scholar
- 10.Japan Society for Cancer Chemotherapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer 28:101–130Google Scholar